KyDo Therapeutics GmbH

KyDo Therapeutics GmbH, based in Dortmund, Germany, focuses on developing innovative covalent-allosteric small molecule inhibitors for oncology, targeting challenging cancer variants to improve treatment outcomes for patients. KyDo Therapeutics GmbH specializes in the development of novel small molecule inhibitors for cancer treatment. Founded in 2024, the company has undergone no major pivots in its business strategy. The firm was established in Dortmund, Germany, and In April 2025, KyDo Therapeutics GmbH raised EUR 4.

45 million in seed funding led by Khanu Management, with participation i&i Bio, VORNvc Management and TU capital. As of April 2026, the company is led by its CEO Matthias Stein-Gerlach. KyDo Therapeutics GmbH focuses on the development of novel covalent-allosteric small molecule inhibitors, specifically targeting oncology applications. Their core product offerings are designed to tackle challenging cancer variants, with the goal of creating first-in-class drugs that could significantly improve treatment outcomes for patients.

These inhibitors operate by modulating the activity of protein targets in a selective manner, thereby offering a therapeutic approach that may enhance efficacy while potentially reducing side effects. KyDo’s primary clients include pharmaceutical companies and research institutions in Europe and North America, where there is a significant demand for innovative cancer therapies. The company’s products are positioned within highly competitive markets that require advanced solutions for unmet medical needs in oncology. KyDo Therapeutics operates primarily through a B2B model, engaging in partnerships and collaborations to facilitate the advancement of its drug discovery platform.

Revenue generation is structured around strategic alliances with larger pharmaceutical companies, which may involve milestone payments and royalties based on the successful development and commercialization of their inhibitors. Additionally, the company may engage in direct agreements with research institutions for the use of its proprietary technologies in preclinical studies. Although specific pricing plans for their products have not been disclosed, the typical structure for such transactions would include upfront fees for access to the technology, followed by performance-based payments contingent on achieving defined development milestones. As KyDo continues to advance its lead programs, it positions itself to capitalize on licensing opportunities within the oncology market.

In April 2025, KyDo Therapeutics GmbH raised EUR 4. 45 million in seed funding led by Khanu Management, with participation i&i Bio, VORNvc Management and TU capital to support its covalent-allosteric drug discovery research. The company is focused on the development of new oncology products and plans to expand its reach into specific markets in Europe and North America. The funding will be utilized to enhance research capabilities and advance their drug development initiatives.